Joseph Burnett Sells 20,000 Shares of ClearPoint Neuro (NASDAQ:CLPT) Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) CEO Joseph Burnett sold 20,000 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $16.12, for a total transaction of $322,400.00. Following the sale, the chief executive officer directly owned 11,565 shares of the company’s stock, valued at approximately $186,427.80. This trade represents a 63.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

ClearPoint Neuro Trading Up 6.5%

Shares of CLPT stock opened at $15.41 on Thursday. The company has a quick ratio of 5.56, a current ratio of 6.37 and a debt-to-equity ratio of 1.84. ClearPoint Neuro, Inc. has a fifty-two week low of $9.76 and a fifty-two week high of $30.10. The firm’s 50 day moving average price is $14.43 and its two-hundred day moving average price is $15.05. The stock has a market cap of $437.95 million, a price-to-earnings ratio of -18.35 and a beta of 0.91.

ClearPoint Neuro (NASDAQ:CLPT) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The business had revenue of $5.36 million during the quarter, compared to analysts’ expectations of $9.60 million. ClearPoint Neuro had a negative net margin of 67.40% and a negative return on equity of 114.28%. On average, analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Institutional Trading of ClearPoint Neuro

Large investors have recently modified their holdings of the business. Parsons Capital Management Inc. RI increased its position in shares of ClearPoint Neuro by 0.7% during the second quarter. Parsons Capital Management Inc. RI now owns 143,486 shares of the company’s stock worth $1,713,000 after acquiring an additional 950 shares during the last quarter. MGO One Seven LLC grew its stake in ClearPoint Neuro by 6.0% during the 3rd quarter. MGO One Seven LLC now owns 19,026 shares of the company’s stock valued at $415,000 after purchasing an additional 1,077 shares in the last quarter. Financial Management Professionals Inc. purchased a new stake in ClearPoint Neuro during the 3rd quarter worth approximately $28,000. Pekin Hardy Strauss Inc. raised its position in shares of ClearPoint Neuro by 3.6% in the 2nd quarter. Pekin Hardy Strauss Inc. now owns 50,575 shares of the company’s stock valued at $604,000 after purchasing an additional 1,750 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in shares of ClearPoint Neuro by 3,076.9% during the 2nd quarter. Allworth Financial LP now owns 2,065 shares of the company’s stock valued at $25,000 after buying an additional 2,000 shares during the last quarter. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CLPT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Wednesday, October 8th. Wall Street Zen lowered ClearPoint Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, ClearPoint Neuro currently has an average rating of “Moderate Buy” and an average target price of $19.67.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.